Restless legs syndrome and drug-induced akathisia in headache patients

CNS Spectrums

Volumn 8, Issue 6, 2003, Pages 450-456

  Young, William B ^a   Piovesan, Elcio J ^a   Biglan, Kevin M ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; GABAPENTIN; METOCLOPRAMIDE; OPIATE AGONIST; PROCHLORPERAZINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AKATHISIA; ARTICLE; CLINICAL EXAMINATION; CLUSTER HEADACHE; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RISK ASSESSMENT; SELF REPORT;

EID: 0037785325     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900018769     Document Type: Article

References (69)

1. Walters AS. Toward a better definition of the restless legs syndrome. Mov Disord. 1995;10:634-642.
2. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
3. Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep. 1994;17:739-743.
4. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47:1435-1441.
5. Chokroverty S. Sleep disorders. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in Clinical Practice. 3rd ed. Boston, Mass: Butterworth-Heinemann; 2000:1781-1827.
6. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology. 1988;38:1845-1848.
7. Walters AS, Hening JW, Kavey N, Chokroverty S, Frank SG. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol. 1988;24:455-458.
8. Trenkwalder C, Stiasny K, Pollmacher T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trail. Sleep. 1995;18:681-688.
9. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology. 1999;52:944-950.
10. Montplaisir J, Nicolas A, Denesle R, Mancilla BG. Restless legs syndrome improved by pramipexole: a double-blind randomized trail. Neurology. 1999;52:938-943.
11. Reuter I, Ellis CM, Chaudhuri KR. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand. 1999;100:163-167.
12. Ondo W. Ropinirole for restless legs syndrome. Mov Disord. 1999;14:138-140.
13. Inoue Y, Mitani H, Nanba K, Kawahara R. Treatment of periodic leg movements disorder and restless legs syndrome with talipexole. Psychiatr Clin Neurosci. 1999;53:283-285.
14. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology. 1999;52:932-937.
15. O'keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Aging. 1994;23:200-203.
16. Sachdev P. The neuropsychiatry of brain iron. J Neuropsychiatr Clin Neurosci. 1993;5:18-29.
17. Allen RP, Mignot E, Ripley B, Nishino S, Earley CJ. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology. 2002;59:639-641.
18. Ulfberg J, Nystrom B, Carter N, Edling C. Restless legs syndrome among working-aged women. Eur Neurol. 2001;46:17-19.
19. Peres MF, Young WB, Kaup AO, Zukennan E, Silberstein SD. Fibromyalgia Is Common In Patients With Transformed Migraine. Neurology. 2001;57:1326-1328.
20. Yunus MB. Psychological aspects of fibromyalgia syndrome: a component of the dysfunctional spectrum syndrome. Baillieres Clin Rheumatol. 1994;8:811-837.
21. Yunus MB. Central sensitivity syndromes: a unified concept for fibromyalgia and other similar maladies. J Indian Rheum Assoc. 2000;8:27-33.
22. Yunus MB. A comprehensive medical evaluation of patients with fibromyalgia syndrome. Rheumatic Dis Clin N Am. 2002;28.
23. Paiva T, Farinha A, Martins A, Batista A, Guilleminault C. Chronic headaches and sleep disorders. Arch Intern Med. 1997;157:1701-1705.
24. Barnes TR. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev. 1987;5:301-319.
25. Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry. 1998;59:69-75.
26. Kurzthaler I, Hummer M, Kohl C, Miller C, Fleischhacker WW. Propranolol treatment of olanzapine-induced akathisia. Am J Psychiatry. 1997;154:1316.
27. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American Double-Blind Olanzapine Trial. Neuropsychopharmacology. 1996;14:111-123.
28. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology. 1995;118:52-56.
29. Miller CH, Hummer M, Oberbauer H, Kurzthaler I, Fleischhacker WW. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacology. 1997;7:51-55.
30. Osswald GM, Karlssen P, Udnaes MH, Farde L. Influence of the rate of administration of raclopride on akathisia and prolactin response. Psychopharmacology. 1994;114:248-256.
31. Farde L. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans - a PET study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology. 1992;107:23-29.
32. Nordstrom AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology. 1992;106:433-438.
33. Barnes TR, Braude WM, Hill DJ. Acute akathisia after oral droperidol and metoclopramide preoperative medication. Lancet. 1982;2:48-49.
34. Sachdev P, Loneragran C. The present status of akathisia. J Nerv Ment Dis. 1991;179:381-389.
35. Lipinski JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989;50:339-342.
36. Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-150.
37. Riley DE, Lang AE. Movement disorders. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in Clinical Practice. 3rd ed. Boston, Mass: Butterworth-Heinemann; 2000:1921-1924.
38. vanPutten T, May PR, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry. 1984;41:1036-1039.
39. Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache. 1997;37:377-382.
40. Richman PB, Allegra J, Eskin B, et al. A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. Am J Emerg Med. 2002;20:39-42.
41. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26:541-546.
42. Tek DS, McClellan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoclopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med. 1990;19:1083-1087.
43. Cameron JD, Lane PL, Speechley M. Intravenous chlorpromazine vs intravenous metoclopramide in acute migraine headache. Acad Emerg Med. 1995;2:597-602.
44. Fisher H. A new approach to emergency department therapy of migraine headache. J Emerg Med. 1995;136:119-122.
45. Ekbom KA. Restless legs syndrome. Neurology. 1960;10:868-873.
46. Peroutka SJ. Dopamine and migraine. Neurology 1997;49:650-656.
47. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997;49:201-206.
48. Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia. 1998;18:174-182.
49. Kraus T, Schuld A, Pollmacher T. Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine. J Clin Psychopharmacol. 2000;19:478-479.
50. Horiguchi J, Yamashita H, Mizuno S, et al. Nocturnal eating/drinking syndrome and neuroleptic-induced restless legs syndrome. Int Clin Psychopharmacol. 1999;14:33-36.
51. Walters AS, Hening W, Rubinstein M, Chokroverty S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep. 1991;14:339-345.
52. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
53. Miller CH, Fleischhacker WW, Ehrmann H, Kane JM. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull. 1990;26:373-376.
54. Fuentenebro FS, Huidobro A, Rivas AT. Restless legs syndrome and paroxetine. Acta Psychiatr Scand. 1996;94:482-484.
55. Diamond BI, Borison RL. Enkephalins and nigrostriatal function. Neurology. 1978;28:1085-1088.
56. Hening WA, Walters A, Kavey N, Frank SG, Cote L, Fahn S. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology. 1986;36:1363-1366.
57. Walters A, Hening W, Chokroverty S, Fahn S. Opioid responsiveness in patients with neuroleptic induced akathisia. Mov Disord. 1986;1:119-128.
58. Drake M. Restless legs with antiepileptic drug therapy. Clin Neurol Neurosurg. 1988;90:151-154.
59. Adler CH. Treatment of restless legs syndrome with gabapentin. Clin Neuropharmacol. 1997;20:148-151.
60. Sachdev P, Loneragran C. Intravenous benztropine and propranolol challenges in tardive akathisia. Psycopharmacology. 1993;113:119-122.
61. Sachdev P, Loneragran C. Intravenous benztropine and propranolol challenges in acute neuroleptic induced akathisia. Clin Neuropharmacol. 1993;16:324-331.
62. Rosebush PI, Mazurek MF. Complicating factors in the analysis of acute drug-induced akathisia. Arch Gen Psychiatry. 1995;52:878-880.
63. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol. 1990;10:12-21.
64. Adler LA, Angrist B, Fritz P, Rotrosen J, Mallya G, Lipinski JF. Lack of efficacy of d-propranolol in neuroleptic induced akathisia. Neuropsychopharmacology. 1991;4:109-115.
65. Miller CH, Fleischhacker WW. Managing antipsychotic induced acute and chronic akathisia. Drug Safety. 2000;22:73-81.
66. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
67. Hudson JI, Pope HG Jr. Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? Am J Psychiatry. 1990;147:552-564.
68. Jacome DE. Blepharoclonus, pseudoasterixis, and restless feet. Am J Med Sci. 2001;322:137-140.
69. Jacome DE. Neuromuscular transmission in migraine: a single-fiber EMG study in clinical subgroups. Neurology. 2002;58:1316.